California Assembly Bill AB2095 Latest Draft

 BILL NUMBER: AB 2095AMENDED BILL TEXT AMENDED IN ASSEMBLY MARCH 18, 2016 INTRODUCED BY Assembly Member Travis Allen FEBRUARY 17, 2016 An act relating to  economic development.   Medi-Cal.  LEGISLATIVE COUNSEL'S DIGEST AB 2095, as amended, Travis Allen.  Economic development.   Medi-Cal: prescriptions.   Existing law establishes the Medi-Cal program, administered by the State Department of Health Care Services, under which health care services are provided to qualified, low-income persons. The Medi-Cal program is, in part, governed and funded by federal Medicaid Program provisions.   This bill would require the Legislative Analyst's Office to conduct or cause to be conducted a study comparing the purchase or administration of brand name prescription medications through the Medi-Cal program to the purchase or administration of biosimilars through the Medi-Cal program, as specified. The bill would require the study to cover the 2013-14 and 2014-15 fiscal years and to be completed on or before January 1, 2018.   Existing law creates various state agencies and authorizes certain of those agencies to regulate the operations of businesses. Existing law, until January 1, 2018, authorizes cities and counties to establish capital investment incentive programs to attract large manufacturing facilities to invest in their communities and to encourage industries, such as high technology, aerospace, automotive, biotechnology, software, and environmental sources and others, to locate and invest in those facilities in California.   This bill would express the intent of the Legislature to enact legislation that would enhance and advance opportunities for California's biotechnology industry.  Vote: majority. Appropriation: no. Fiscal committee:  no   yes  . State-mandated local program: no. THE PEOPLE OF THE STATE OF CALIFORNIA DO ENACT AS FOLLOWS:  SECTION 1.   The Legislative Analyst's Office shall conduct or cause to be conducted a study comparing the purchase or administration of brand name prescription medications through the Medi-Cal program to the purchase or administration of biosimilars through the Medi-Cal program. The study shall cover the 2013-14 and 2014-15 fiscal years and shall be completed on or before January 1, 2018. The study shall breakdown the information by the age, ethnicity, and gender of the Medi-Cal recipients who purchase those medications or to whom the medications are administered.   SECTION 1.   It is the intent of the Legislature to enact legislation that would enhance and expand opportunities for California's biotechnology industry.